Non-invasive and inexpensive test may detect Alzheimers Scientists from Durin Systems.

The research team’s findings appear on-line in PLoS ONE. More than 100 years after it was first described, Alzheimer’s affects nearly 36 million people worldwide, yet there remains only 1 definitive way to diagnose the condition – the direct examination of brain tissue following the patient’s death ‘There’s a dire dependence on an accurate, relatively noninvasive and inexpensive diagnostic check for Alzheimer’s,’ said Robert Nagele, PhD, founder of Durin Technologies, Inc., and a professor at the UMDNJ-College of Osteopathic Medicine.Such remedies could complement and augment existing tumor drugs and bring about far better and safer treatments for cancer individuals. Prof Lam Kong Peng, Executive Director of BTI, stated: This collaboration underscores the potency of BTI's antibody analysis and allows us to leverage on Roche's experience to develop novel antibody-based therapeutics. We are self-confident that this will be the start of an extended and fruitful partnership that won’t only benefit human wellness but also the biologics industry. Dr. Juan-Carlos Lopez, Mind of the Roche Pharma Study and Early Advancement Academic Relations and Collaborations, said: Accessing external technology through partnerships with general public sector research institutes is essential for identifying first-in-class or best-in-class opportunities.